These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 15754530)

  • 61. Platinums: extending their therapeutic spectrum.
    Muggia FM; Fojo T
    J Chemother; 2004 Nov; 16 Suppl 4():77-82. PubMed ID: 15688617
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Particular aspects of platinum compounds used at present in cancer treatment.
    Desoize B; Madoulet C
    Crit Rev Oncol Hematol; 2002 Jun; 42(3):317-25. PubMed ID: 12050023
    [TBL] [Abstract][Full Text] [Related]  

  • 63. New insights into the biotransformation and pharmacokinetics of oxaliplatin.
    Jerremalm E; Wallin I; Ehrsson H
    J Pharm Sci; 2009 Nov; 98(11):3879-85. PubMed ID: 19340883
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Long-term platinum retention after treatment with cisplatin and oxaliplatin.
    Brouwers EE; Huitema AD; Beijnen JH; Schellens JH
    BMC Clin Pharmacol; 2008 Sep; 8():7. PubMed ID: 18796166
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Platinum based radiochemotherapies: Free radical mechanisms and radiotherapy sensitizers.
    Fong CW
    Free Radic Biol Med; 2016 Oct; 99():99-109. PubMed ID: 27417937
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Rationally designed oxaliplatin-nanoparticle for enhanced antitumor efficacy.
    Paraskar A; Soni S; Roy B; Papa AL; Sengupta S
    Nanotechnology; 2012 Feb; 23(7):075103. PubMed ID: 22275055
    [TBL] [Abstract][Full Text] [Related]  

  • 67. A comparative binding of platinum anti-tumour compounds to plasma proteins in the rat (in vivo) and mouse (in vitro).
    Perera A; Jackson H; Sharma HL; McAuliffe CA; Fox BW
    Chem Biol Interact; 1992 Dec; 85(2-3):199-213. PubMed ID: 1493609
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Nucleolar damage correlates with neurotoxicity induced by different platinum drugs.
    McKeage MJ; Hsu T; Screnci D; Haddad G; Baguley BC
    Br J Cancer; 2001 Oct; 85(8):1219-25. PubMed ID: 11710838
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Pharmacokinetics and pharmacodynamics of serum platinum of gynecologic cancer patients treated with nedaplatin.
    Matsumoto Y; Ishiko O; Nakagawa E; Sumi T; Hyun Y; Ando Y; Ogita S
    Oncol Rep; 2001; 8(6):1269-73. PubMed ID: 11605047
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Molecular determinants of the cytotoxicity of platinum compounds: the contribution of in silico research.
    Vekris A; Meynard D; Haaz MC; Bayssas M; Bonnet J; Robert J
    Cancer Res; 2004 Jan; 64(1):356-62. PubMed ID: 14729645
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Searching for the Magic Bullet: Anticancer Platinum Drugs Which Can Be Accumulated or Activated in the Tumor Tissue.
    Galanski MS; Keppler BK
    Anticancer Agents Med Chem; 2007 Jan; 7(1):55-73. PubMed ID: 17266505
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Cytostatic platinum complexes: an unexpected discovery with considerable consequences].
    Köpf-Maier P; Köpf H
    Naturwissenschaften; 1986 May; 73(5):239-47. PubMed ID: 3736675
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The tissue distribution in rats of [195mPt]carboplatin following intravenous, intraperitoneal and oral administration.
    Tinker N; De Spiegeleer B; Sharma H; Jackson H; McAuliffe C; Reman JP
    Int J Rad Appl Instrum B; 1990; 17(4):427-36. PubMed ID: 2201668
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Interactions between proteins and platinum-containing anti-cancer drugs.
    Bischin C; Lupan A; Taciuc V; Silaghi-Dumitrescu R
    Mini Rev Med Chem; 2011 Mar; 11(3):214-24. PubMed ID: 21534930
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Differential anti-proliferative properties of novel hydroxydicarboxylatoplatinum(II) complexes with high or low reactivity with thiols.
    Buraczewska I; Bouzyk E; Kuduk-Jaworska J; Waszkiewicz K; Gasińska A; Szumiel I
    Chem Biol Interact; 2000 Dec; 129(3):297-315. PubMed ID: 11137067
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Chronotoxicity of nedaplatin in rats.
    Cui Y; Sugimoto K; Kawai Y; Sudoh T; Gemba M; Fujimura A
    Chronobiol Int; 2004 Jul; 21(4-5):601-11. PubMed ID: 15470957
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Platinum-based agents for individualized cancer treatment.
    Chen X; Wu Y; Dong H; Zhang CY; Zhang Y
    Curr Mol Med; 2013 Dec; 13(10):1603-12. PubMed ID: 24206132
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.
    Bates PI; Sharma HL; Murrer BA; McAuliffe CA
    Cancer Chemother Pharmacol; 1996; 39(1-2):170-5. PubMed ID: 8995517
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Cellular distribution and cellular reactivity of platinum (II) complexes.
    Lindauer E; Holler E
    Biochem Pharmacol; 1996 Jul; 52(1):7-14. PubMed ID: 8678910
    [TBL] [Abstract][Full Text] [Related]  

  • 80. The effect of reduced osmolarity on platinum drug toxicity.
    Smith E; Brock AP
    Br J Cancer; 1989 Jun; 59(6):873-5. PubMed ID: 2660897
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.